thought call strong
growth pipelin could
want larg cap
better-than-expect trikafta launch highlight strong fundament support cf
revenu pipelin repres addit upsid fulli reflect share
initi trikafta number far exceed expect sale vs consensu
demonstr commerci prowess vertex also encourag symdeko
orkambi technic miss evid exist patient switch trikafta
look ahead continu believ trikafta launch remain robust continu
penetr us market along eventu expans ou despit revenu
benefit inventori build trikafta launch revenu still
expect still somewhat higher end project higher trikafta
revenu vs consensu overal revenu slightli ahead
guidanc believ conserv beatabl
addit reimburs agreement ou could drive cf revenu well
repres consensu expect along reimburs full portfolio
countri limit agreement franc view strong cf base busi
continu outperform allow vertex focu grow pipelin provid
option continu bd given vertex continu execut commerci
pipelin perspect reiter outperform rate increas tp
pipelin becom relev part vertex stori still set favor
risk/ reward model limit credit vertex pipelin given earlier stage
develop howev think diversifi asset provid interest option
potenti upsid posit result start better understand pipelin
valu data readout phase poc studi updat data
scd/ beta thalassemia
model updates/risk ep updat due revis revenu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
vertex engag develop commerci therapeut
rare diseas includ main franchis cystic fibrosi
scenario assum dcf valu share
cut sg respect assum
posit proof-of-concept data next gener cf asset
also assum posit data updat pipelin asset vx-
gene-edit system
grey sky scenario model less credit trikafta due
lower expect commerci perform regulatori delay
 close
pipelin updat look cf franchis vertex file ema
trikafta patient older addit phase studi children age continu
enrol switch non-cf pipelin vertex expect clinic data
antitrypsin franchis peopl two mutat second
asset current on-going phase
vertex expect initi phase proof-of-concept studi evalu
treatment focal segment glomerulosclerosi fsg
gene therapi crispr-partn franchis vertex expect updat clinic data
on-going phase studi sickl cell diseas beta thalassemia recal
saw initi data two patient novemb move pain franchis
compani discontinu asset target channel due unfavor pk
model adjust increas estim trikafta base strong launch
assum untreat patient elig symdeko start trikafta furthermor
assum consider patient switch trikafta mainli symdeko also
kalydeco orkambi result forecast revenu slightli
revenu guidanc believ conserv guidanc
non-gaap ep weve reduc expens
valuat target price deriv dcf analysi use wacc
termin growth forecast cash flow account known expect
product launch patent expir competit threat current commerci
portfolio pipelin
vertex residu cf opportun ex cf opportun ex revenu loss incom cs dilut cs charl martineau univers toronto januari
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv vertex investig product
commerci sale
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
